Avia Pharma today announces the entering of a strategic partnership and distribution agreement with Pohl-Boskamp, a Germany-based pharmaceutical company, for the Nordic markets. Under the agreement, Avia Pharma will act as Pohl-Boskamp’s official distributor in the Nordic region for the following products and countries:

GeloRevoice® – unique throat lozenges that are specially developed for frequent speakers and singers. Thanks to the special hydrogel complex, typical voice problems such as throat irritation, tickling of the throat and hoarseness are quickly and lastingly relieved. (Denmark, Norway and Sweden)

Nitrolingual® – a sublingual nitroglycerin spray for the treatment of angina pectoris. (Denmark, Norway and Sweden)

Gepan® instill – a bladder instillation containing chondroitin sulphate for the treatment of chronic forms of cystitis, e. g. interstitial cystitis, overactive bladder, chronic recurrent urinary tract inflammation and radiation cystitis. (Denmark, Finland, Norway and Sweden)

The partnership represents an important step in Avia Pharma’s strategy to expand its Nordic portfolio with high-quality specialty products that address clear patient needs.

“We are delighted to enter into this collaboration” says Marie Wikman, Head of Nordics at Avia Pharma. “Pohl-Boskamp’s strong product portfolio and long-standing expertise complement Avia Pharma’s Nordic portfolio and commercial capabilities. We look forward to continuing developing these products in the Nordic market, making them more widely available to healthcare professionals and patients throughout the region”.

“We are looking forward to working with Avia Pharma’s experienced team. Our new partnership is an important step toward raising the awareness of our high-quality-products in the Nordic markets and helping patients recover quickly – in line with our motto: Feel how it works.” says Bodo Heibrock, Senior Director International Sales & Business Development at Pohl Boskamp.

For further information, please contact:

Jacob Calmvik, CEO
Email: Jacob.calmvik@aviapharma.se

Avia Pharma AB (“Avia”), a Sweden‑based pharmaceutical company focusing on OTC products across Northern Europe, today announced that it has completed the acquisition of the Swedish consumer health company Allderma AB (“Allderma”). The transaction closed on 27 February 2026 and represents another important step in Avia’s strategy to expand its presence within medically positioned consumer health and dermatology.

Allderma will add approximately EUR 14 million in annual sales to Avia’s growing portfolio and is expected to contribute positively to the company’s continued growth trajectory in the Nordic region and beyond. The acquisition further strengthens Avia’s commercial platform, brand portfolio and long‑term ability to scale differentiated consumer health products across its core European markets.

Through the acquisition, Avia gains access to Allderma’s rapidly growing portfolio of well‑established brands. Key products include Daxxin, a dermatology‑focused shampoo and shower formulation developed to support the treatment of dandruff, dry scalp and psoriasis‑related symptoms; Terclara, a pharmaceutical treatment for nail fungus with strong market recognition in Sweden and Norway; Hårkontroll, a food supplement designed to promote stronger hair growth and improved hair quality; and Lactiplus, a probiotic supplement supporting digestive health and overall wellbeing. Together, these products form a highly complementary portfolio that aligns closely with Avia’s focus on scientifically grounded, pharmacy‑recommended solutions.

The addition of Allderma’s brands enhances Avia’s dermatology offering while also expanding its presence within adjacent everyday health categories. Avia sees meaningful opportunities to further invest in brand development, geographic expansion and lifecycle management across the portfolio, supported by the company’s established Nordic infrastructure and growing European footprint.

“We are very impressed by the Allderma team, their entrepreneurial spirit and the strong growth the company has delivered in recent years,” said Jacob Calmvik, CEO of Avia Pharma. “The portfolio is highly complementary to our existing business and strengthens our position within dermatology and consumer health. We look forward to working with our new colleagues in the team to further develop the brands, expand their geographic reach and continue delivering high‑quality products that create real value for pharmacies, healthcare professionals and patients across our markets.”

For further information, please contact:

Jacob Calmvik, CEO
Email: Jacob.calmvik@aviapharma.se
Website: www.aviapharma.se

About Avia Pharma

Avia Pharma is a pharmaceutical company founded by professionals with extensive experience in the pharmaceutical and pharmacy sectors. The company operates throughout Northern Europe with offices in Stockholm, Helsinki, Munich and Greven, focusing on core therapeutic areas including dermatology, women’s health, allergy and everyday health. Through collaborations with international partners and its own brands, Avia Pharma markets pharmaceuticals, OTC products and medical devices that contribute to improved health and quality of life.

About Allderma
Allderma is a Sweden-based consumer healthcare company that develops, markets and sells pharmacy-distributed healthcare products across the Nordic region. Founded in 2001 and backed by 3iM Equity Partners since 2020, the company offers a diversified portfolio spanning OTC pharmaceuticals, medical devices, cosmetics and supplements addressing common conditions in dermatology and everyday health, supported by a strong pipeline and a track record of profitable growth.

Tolfer is a new iron supplement developed for people with increased iron needs who experience gastrointestinal discomfort from certain traditional iron salts, such as ferrous sulfate. The product is now being launched in Sweden and Finland by Avia Pharma, and is based on the patented IHAT technology (Iron Hydroxide Adipate Tartrate) – designed to mimic how iron from food is absorbed and to reduce stomach-related discomfort.

Some individuals who take iron supplements experience side effects such as nausea, constipation or diarrhea.¹ This may partly be due to certain traditional iron salts dissolving rapidly in the stomach. Excess free iron can irritate the mucosal lining and affect the gut microbiota.² IHAT differs from traditional forms of iron through its particle structure and absorption pathway, where uptake resembles how iron from food is absorbed.³ The small, stable iron particles in Tolfer do not need to dissolve in the stomach but are absorbed in a protected form – which may be gentler on the stomach.

– Many pregnant women need iron supplements but stop taking them because they experience stomach-related discomfort. There is a clear demand for iron supplements that are better tolerated and more stomach-friendly. New forms of iron that are absorbed in a less irritating way are therefore a very welcome addition to the market – especially for pregnant women, who have a particularly high need for alternatives, says Johanna Ekmark, Nordic Commercial Product Manager OTC at Avia Pharma.

About the IHAT technology

IHAT (Iron Hydroxide Adipate Tartrate) is a new form of iron developed to mimic how iron from food is absorbed in the body. The particles are stable, very small and resemble the structure of ferritin, the body’s natural iron storage protein. Unlike traditional iron salts, IHAT does not dissolve in the stomach but is absorbed in a protected form,^3,4 which reduces the likelihood of chemical reactions that can irritate the intestinal lining.² In clinical studies, IHAT has demonstrated iron absorption comparable to traditional iron forms^5,6 and favourable gastrointestinal tolerability in the populations studied⁶.

About iron

Iron is an essential mineral that contributes to the normal formation of red blood cells and hemoglobin, oxygen transport in the body, normal cognitive function and reduced tiredness and fatigue.⁷ Despite this, iron deficiency is one of the world’s most common nutrient deficiencies,_⁸ particularly among menstruating women, pregnant women, vegans and athletes. During pregnancy, iron requirements increase substantially because the body must produce more blood for both the mother and the growing fetus, while also building iron stores ahead of childbirth.⁹ Iron needs rise from around 15 mg per day for a woman of reproductive age¹⁰ to 27 mg per day during pregnancy.¹¹

About iron deficiency

Iron deficiency is one of the world’s most common nutritional deficiencies. According to WHO, over 30% of women of reproductive age and more than 35% of pregnant women have anemia¹² with iron deficiency being the most common cause. Globally, nearly one quarter of the world’s population is estimated to have anemia, corresponding to approximately 1.9 billion people.¹³

Despite the high prevalence of iron deficiency, many people discontinue iron supplementation prematurely due to gastrointestinal side effects such as nausea, constipation and diarrhea.

For more information, please contact:

Johanna Ekmark, Nordic Commercial Product Manager OTC

johanna.ekmark@aviapharma.se

+46 733 809 809

About Avia Pharma

Avia Pharma is a pharmaceutical company founded in 2016 by professionals with extensive experience in the pharmaceutical and pharmacy sectors. The company operates throughout Northern Europe with offices in Stockholm, Helsinki, Munich and Greven, focusing on five core therapeutic areas: women’s health, urology, dermatology, allergy and everyday health. Avia Pharma reported revenues exceeding EUR 55 million in 2024 and continues to grow both organically and through acquisitions in Northern Europe. Through collaborations with international partners and its own brands, Avia Pharma markets pharmaceuticals, OTC products and medical devices that contribute to better health and improved quality of life.

1 Tolkien Z et al. Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis. PLOS One. 2015;10(2):e0117383. 

2 Bloor SR et al. Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota.Gastroenterology Insights. 2021;12(2):33.

3 Pereira DIA et al. Nanoparticulate iron(III) oxo-hydroxide delivers safe iron that is well absorbed and limits GI side effects. Nanomedicine: NBM. 2014;10(12):1877-1886.

4 Puga AM et al. Iron Supplementation at the Crossroads of Nutrition and Pharmacology. Nutrients. 2022;14(9):1926.

5 EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). “Safety of iron hydroxide adipate tartrate as a novel food and as a source of iron.” EFSA Journal. 2021;19(12):6935.

6 Mohammed N.I. et al. “A novel nano-iron supplement (IHAT) versus standard treatment for iron deficiency anaemia in children 6–35 months (IHAT-GUT trial).” EClinicalMedicine (The Lancet), 2021.

7 European Food Safety Authority (EFSA), Scientific Opinion on the substantiation of health claims related to iron and formation of red blood cells and haemoglobin, oxygen transport, reduction of tiredness and fatigue, EFSA Journal 8(10):1740 (2010).

8 World Health Organization. Anaemia – Fact sheet. 10 feb 2025. Tillgänglig: https://www.who.int/news-room/fact-sheets/detail/anaemia (hämtad 13 nov 2025).

9 Institute of Medicine (US) Committee on Nutritional Status During Pregnancy and Lactation. (1990). Nutrition During Pregnancy: Part I: Weight Gain; Part II: Nutrient Supplements. National Academy Press. Retrieved November 13, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK235228/

10 Livsmedelsverket, Hälsosamma matvanor under graviditet och amning, Rapport L 2020 nr 08, 2020. Tillgänglig: https://www.livsmedelsverket.se/4aa16f/globalassets/publikationsdatabas/rapporter/2020/l-2020-nr-08-halsosamma-matvanor-under-graviditet-och-amning.pdf (hämtad: 2025-11-27).

11 NIH Office of Dietary Supplements, Iron – Health Professional Fact Sheet, 2025. 

12 World Health Organization. Anaemia in women of reproductive age – Global Health Observatory data. WHO, 2024.

13 World Health Organization. Global anaemia estimates, 2021 edition. Geneva: WHO, 2023.

Avia Pharma is expanding its self-care portfolio with the launch of Oralmedic, a fast and effective treatment for mouth ulcers, across the Nordic region.

– We are proud to bring Oralmedic back to the Nordic markets. It has been highly requested by both consumers and pharmacies since its withdrawal from shelves in 2023. The relaunch strengthens our offering within oral care and meets a clear demand, says Marie Wikman, Head of Nordics at Avia Pharma.

Oralmedic will be available from September in pharmacies across Sweden, Norway, Denmark, and Finland.

Avia Pharma has entered into an exclusive agreement with Nemysis Limited to introduce Tolfer, a next-generation iron supplement containing IHAT (Iron Hydroxide Adipate Tartrate), to the Nordic market. The partnership aims to provide a well-tolerated and highly bioavailable solution for the prevention and treatment of iron deficiency across the region.

Marie Wikman, Head of Nordics Avia Pharma, states: “We are very excited to bring Tolfer to our markets. We believe this unique product will support many of our customers and strengthen our ability to fulfil our mission of making Northern Europe a healthier place, particularly within our Women’s Health market focus.”

Commenting on the Agreement, Marco Cartolari, Chief Operating Officer Nemysis remarks “We are pleased to add this collection of territories to IHAT’s footprint and that of the Tolfer brand and to be working with a fast-growing partner such as Avia and its team. This collaboration is a robust strategic fit for both parties and we look forward to all stakeholders benefitting from Tolfer in the covered territories”.

Tolfer will be available in pharmacies in Sweden, Finland and Denmark.

Avia Pharma is announcing its official representation in the Nordics of Theramex, a global specialty pharmaceutical company that specializes in women’s health products.  

Based in London, Theramex is a global pharmaceutical company dedicated to Women’s Health in over eighty countries, across five continents. The Group is driven by a vision to be a leader in women’s health care by providing innovative, effective solutions that care for and support women as they advance through each stage of their lives.

This prestigious partnership includes a series of pharmaceuticals within Hormone Replacement Therapy (HRT) and contraceptives.

The representation of Theramex in the Nordics is in line with Avia Pharma’s business growth strategy to grow its core business and explore new opportunities and partnerships.

“This representation also stems from the development of our Women’s Health Business Unit, set to be one of our flagship projects for the coming years,” says Marie Wikman.

“We are excited to partner with Avia Pharma in the Nordics who, like Theramex, share our commitment to women’s health and to improve access to high quality treatments. We look forward to this new collaboration and we are sure that together, we will support many women to live a better and more empowered life,” said Rob Stewart, CEO of Theramex.

“Through our representation of Theramex, Avia Pharma is now going to be even better positioned to provide education and support around important issues and daily realities faced by women every day, including menopause” concludes Marie Wikman.

Avia Pharma Holding AB (“Avia” or the “Company”) has completed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition, Avia adds a strong dermatology brand portfolio in Germany to its platform, including, Allpresan, the German market leader in foam-based foot care. The company generates annual revenues of c. EUR 15m and has c. 70 employees.

Jacob Calmvik, Co-Founder and CEO of Avia, comments: “We are thrilled to welcome Neubourg to Avia. The acquisition fits perfectly with our strategy of acquiring strong local brands, such as Allpresan, in the DACH region.”

“I believe Avia will be a very strong long-term owner of Neubourg and that they will be able to develop our brands further. The Neubourg portfolio also complements Avia’s current dermatology portfolio in a good way. I am very pleased we have been able to reach this agreement.”, says Thomas Neubourg, CEO and co-owner of Neubourg.

For further information, please contact:
Jacob Calmvik, CEO of Avia,  jacob.calmvik@aviapharma.se

About Avia Pharma
Avia is a leading Swedish OTC/Rx distribution platform with presence in the Nordics and Germany, focusing on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products with brands such as Nix, Duroferon and Allergika. With the most recent acquisition of Neubourg, Avia has an annual turnover of more than SEK 600m. Learn more about Avia Pharma at www.aviapharma.se/

About Neubourg
Neubourg was founded in 1998 and is a German dermatology company with brands such as Allpresan, Podoexpert and Onyfix. It has built its market position via proprietary technology and is recognized by pharmacies and consumers as the market leader in its niches. Learn more about Neubourg at www.neubourg.com     

During January, Avia Pharma Holding AB (“Avia” or the “Company”), welcomed Impilo AB as a new owner and partner to the co-founders. Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies.

The partnership with Impilo will allow Avia to execute on its strategy and ambition of building a leading Northern European OTC / Rx platform through organic and inorganic growth.

Avia was founded in 2016 and focuses on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products. The Company has successfully executed on its strategy to build its own brand portfolio and to grow its Northern European presence over time, through a combination of M&A (6 since inception), in-licensing of additional products and growing market share across the portfolio. Avia is today a well-diversified platform present across the Nordics and Germany with headquarters in Stockholm, Sweden, and with offices in Germany and Finland.

Jacob Calmvik, Co-Founder and CEO of Avia, comments: “The partnership with Impilo is an important step for Avia and will enable us to fully execute on our strategy. Together with Impilo we will continue to scale the platform at a high pace through organic and inorganic growth initiatives. Further, we are happy to welcome Per Edelmann, who comes with vast industry experience, as the new chairperson of the board.”

As a testament to the ambitious growth agenda, in the week after Impilo closed its investment in Avia, the Company closed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition of Neubourg, Avia adds a strong dermatology brand portfolio in Germany to its platform, including, Allpresan, the German market leader in foam-based foot care.

“Impilo is very excited to partner with Avia management and the co-founders Jacob Calmvik and Jostein Lønberg. We have followed Avia’s growth journey closely and look forward to supporting the Company in its effort to build a leading platform in the OTC/Rx space”, says Carolina Oscarius Dahl, Partner at Impilo

For further information, please contact:
Jacob Calmvik, CEO of Avia,  jacob.calmvik@aviapharma.se
Carolina Oscarius Dahl, Partner at Impilo,  carolina.oscarius.dahl@impilo.se

About Avia Pharma
Avia is a leading Swedish OTC/Rx distribution platform with presence in the Nordics and Germany, focusing on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products with brands such as Nix, Duroferon and Allergika. With the most recent acquisition of Neubourg, Avia has an annual turnover of more than SEK 600m. Learn more about Avia Pharma at www.aviapharma.se/

About Impilo
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare and care services, and other health-related areas. The Company strives to increase the value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of investments and has raised c. SEK 10 billion in capital from leading Nordic and international investors since its inception in 2017. Learn more about Impilo at www.impilo.se/en/

Avia Pharma has today completed the acquisition of ACO Vitamin D water and will as the new marketing authorisation holder re-launch the pharmaceutical in the Swedish market in Q4 this year.

“The acquisition allows us to continue offering this complement to D-vitamin oil”, says Marie Wikman, Business Unit Director Avia Pharma. For further information, please contact Marie Wikman, marie.wikman@aviapharma.se, +46 708 16 88 16.

Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida.

Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region.

75% of women are affected at least once during their lifetime es. 90% of those affected are considered uncomplicated and Candida (fungus) is the cause.

Resistance to Candida treatment is a major and growing problem, a sharp increase has been seen in recent decades.

In vitro and in vivo studies show that nystatin has a good effect and there has been no development of resistance in Candida strains. “In addition Nyvigan offers no systemic exposure, no known drug interactions and can be used during any stage of pregnancy and breast-feeding”, says Marie Wikman, Business Unit Director Avia Pharma. For further information, please contact Marie Wikman, marie.wikman@aviapharma.se, +46 708 16 88 16.